BFRGW Bullfrog AI Holdings Inc. Warrants

Price
$0.45
Increased by +9.76%
Dollar volume (20D)
1.74 K
ADR%
11.11
Shares float
0.00
Shares short
1.33 K [N/A%]
Shares outstanding
0.00
Market cap
N/A
Beta
N/A
Price/earnings
N/A
20D range
0.33 0.62
50D range
0.33 0.62

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.

It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data.

The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease.

The company was founded in 2017 and is based in Gaithersburg, Maryland.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 65.00 K
Increased by +N/A%
-1.25 M
Decreased by -63.85%
Decreased by -1.93 K%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-1.48 M
Decreased by -90.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 10.00 K
Increased by +N/A%
-1.33 M
Decreased by -134.05%
Decreased by -13.26 K%
Decreased by N/A%
Dec 31, 22 10.00 K
Increased by +N/A%
-695.52 K
Decreased by -331.84%
Decreased by -6.96 K%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-764.69 K
Decreased by -314.54%
Decreased by N/A%
-
Jun 30, 22 0.00
Decreased by N/A%
-775.92 K
Decreased by -308.96%
Decreased by N/A%
-
Mar 31, 22 0.00 - -566.36 K -
Decreased by N/A%
-
Dec 31, 21 0.00 - -161.06 K -
Decreased by N/A%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY